Clinical Trials Directory

Trials / Unknown

UnknownNCT01049685

Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy

Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
36 (actual)
Sponsor
UPECLIN HC FM Botucatu Unesp · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary endpoint: virological success (HIV RNA \<50 copies/mL) in the first six months and at the end of the study.

Detailed description

Background: Either LPV/r or EFZ plus a two nucleoside reverse-transcriptase inhibitors (NRTIs) are recommended by the current guidelines all around the world as the main background drugs for initial therapy of human immunodeficiency virus type 1 (HIV-1) infection. This indication is based in results of clinical trials, but patients who participate in these studies usually are greatly motivated to continue their prescribed regimen, and can be different from the "real life". Therefore, clinical practice often cannot reproduce published results. Methods: A retrospective longitudinal cohort study was performed with 36 naïve-treatment patients, who started therapy with LPV/r or EFZ, with follow-up of 36 months. The primary endpoint was virological success (HIV RNA \<50 copies/mL) in the first six months and at the end of the study. Effectiveness was examined comparing time to virological failure and CD4 recovery.

Conditions

Interventions

TypeNameDescription
DRUGFirst-line Antiretroviral Therapy* Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background * Efavirenz: 01 capsules day, plus NRTI background

Timeline

Start date
2006-08-01
Primary completion
2009-12-01
Completion
2010-03-01
First posted
2010-01-14
Last updated
2010-02-15

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01049685. Inclusion in this directory is not an endorsement.